

**Amendments to the Claims:**

The listing of claims will replace all prior versions, and listings, of claims in the application.

**Listing of Claims:**

Claim 1. (Currently Amended) A peptide selected from the group ~~comprising~~ consisting of:

R-Asn-Gly-Val-Gly- His- Gly-Phe-Gly-Asn-Gly-Val-Gly-Pro-Gly-Thr-Gly-Pro-Gly-Ser-Gly-R' (I) (SEQ ID NO: 1)

R-Gly-Pro-Gly- Val- Gly-Phe-Gly-Lys-Gly-Ile-Gly-Thr-Gly-Arg-Gly-Pro-Gly-Pro-Gly-Gln-R' (II) (SEQ ID NO: 2)

R-Gln-Gly-Pro-Gly-Pro-Gly-Arg-Gly-Thr-Gly-Ile-Gly-Lys-Gly-Phe-Gly-Val-Gly-Pro-Gly-R' (III) (SEQ ID NO: 3) and

R-Gly-Ser-Gly- Pro- Gly-Thr-Gly-Pro-Gly-Val-Gly- Asn-Gly-Gly-Phe-Gly-His-Gly-Val-Gly-Asn-R' (IV) (SEQ ID NO: 4)

where R is H- or COCH<sub>3</sub>, R' is COOH or CONH<sub>2</sub> and each amino acid has the L or D configuration.

Claim 2. (Currently Amended) A pharmaceutical composition comprising an effective dose of at least a peptide compound selected from the group ~~comprising~~ consisting of:

R-Asn-Gly-Val-Gly- His- Gly-Phe-Gly-Asn-Gly-Val-Gly-Pro-Gly-Thr-Gly-Pro-Gly-Ser-Gly-R' (I) (SEQ ID NO: 1)

R-Gly-Pro-Gly- Val- Gly-Phe-Gly-Lys-Gly-Ile-Gly-Thr-Gly-Arg-Gly-Pro-Gly-Pro-Gly-

Gln-R' (II) (SEQ ID NO: 2)

R-Gln-Gly-Pro-Gly-Pro-Gly-Arg-Gly-Thr-Gly-Ile-Gly-Lys-Gly-Phe-Gly-Val-Gly-Pro-Gly-R' (III) (SEQ ID NO: 3) and

R-Gly-Ser-Gly- Pro- Gly-Thr-Gly-Pro-Gly-Val-Gly- Asn-Gly-Gly-Phe-Gly-His-Gly-Val-Gly-Asn-R' (IV) (SEQ ID NO: 4)

where R is H- or COCH<sub>3</sub>, R' is COOH or CONH<sub>2</sub> and each amino acid has the L or D configuration, and at least ~~a pharmaceutical~~ one pharmaceutically acceptable inert ingredient.

Claim 3. (Currently Amended) A method of treating a patient suffering from Multiple Sclerosis, ~~said method~~ comprising:

administering to a patient in need thereof an effective amount of a peptide compound selected from the group ~~comprising~~ consisting of:

R-Asn-Gly-Val-Gly- His- Gly-Phe-Gly-Asn-Gly-Val-Gly-Pro-Gly-Thr-Gly-Pro-Gly-Ser-Gly-R' (I) (SEQ ID NO: 1)

R-Gly-Pro-Gly- Val- Gly-Phe-Gly-Lys-Gly-Ile-Gly-Thr-Gly-Arg-Gly-Pro-Gly-Pro-Gly-Gln-R' (II) (SEQ ID NO: 2)

R-Gln-Gly-Pro-Gly-Pro-Gly-Arg-Gly-Thr-Gly-Ile-Gly-Lys-Gly-Phe-Gly-Val-Gly-Pro-Gly-R' (III) (SEQ ID NO: 3) and

R-Gly-Ser-Gly- Pro- Gly-Thr-Gly-Pro-Gly-Val-Gly- Asn-Gly-Gly-Phe-Gly-His-Gly-Val-Gly-Asn-R' (IV) (SEQ ID NO: 4)

where R is H- or COCH<sub>3</sub>, R' is COOH or CONH<sub>2</sub> and each amino acid has the L or D configuration.

Claim 4. (New) A peptide having the sequence of:

R-Asn-Gly-Val-Gly- His- Gly-Phe-Gly-Asn-Gly-Val-Gly-Pro-Gly-Thr-Gly-Pro-Gly-Ser-

Gly-R'. (I) (SEQ ID NO: 1)

where R is H- or COCH<sub>3</sub>, R' is COOH or CONH<sub>2</sub> and each amino acid has the L or D configuration.

Claim 5. (New) A pharmaceutical composition comprising an effective dose of a peptide compound having the sequence of:

R-Asn-Gly-Val-Gly- His- Gly-Phe-Gly-Asn-Gly-Val-Gly-Pro-Gly-Thr-Gly-Pro-Gly-Ser-

Gly-R' (I) (SEQ ID NO: 1)

where R is H- or COCH<sub>3</sub>, R' is COOH or CONH<sub>2</sub> and each amino acid has the L or D configuration, and at least one pharmaceutically acceptable inert ingredient.

Claim 6. (New) The composition according to Claim 5, wherein the composition is in the form of pills, capsules, sugar coated pills, granules, solutions or syrups for oral administration; unguents or plasters for topical administration; suppositories for rectal administration or sterile solutions for injectable, inhalation or ophthalmic administration.

Claim 7. (New) The composition according to Claim 5, wherein the at least one pharmaceutically acceptable inert ingredient is selected from the group consisting of preservatives, stabilizers, surface-active agents, buffers, salts which regulate osmotic pressure, emulsifying agents, sweeteners, dyes and flavoring agents.

Claim 8. (New) A method of treating a patient suffering from Multiple Sclerosis, comprising:

administering to a patient in need thereof an effective amount of a peptide compound having the sequence of:

R-Asn-Gly-Val-Gly- His- Gly-Phe-Gly-Asn-Gly-Val-Gly-Pro-Gly-Thr-Gly-Pro-Gly-Ser-

Gly-R' (I) (SEQ ID NO: 1)

where R is H- or COCH<sub>3</sub>, R' is COOH or CONH<sub>2</sub> and each amino acid has the L or D configuration.

Claim 9. (New) The method of treating a patient suffering from Multiple Sclerosis according to Claim 8, wherein from 1 to 100 mg/kg/day of said peptide compound is administered to a subject.

Claim 10. (New) A method of preventing the onset of Multiple Sclerosis in a human being, comprising:

administering to a patient an effective amount of a peptide compound having the sequence of:

R-Asn-Gly-Val-Gly- His- Gly-Phe-Gly-Asn-Gly-Val-Gly-Pro-Gly-Thr-Gly-Pro-Gly-Ser-

Gly-R' (I) (SEQ ID NO: 1)

where R is H- or COCH<sub>3</sub>, R' is COOH or CONH<sub>2</sub> and each amino acid has the L or D configuration.

Claim 11. (New) A peptide selected from the group consisting of:

R-Asn-Gly-Val-Gly- His- Gly-Phe-Gly-Asn-Gly-Val-Gly-Pro-Gly-Thr-Gly-Pro-Gly-Ser-

Gly-R' (I) (SEQ ID NO: 1) and

R-Gly-Ser-Gly- Pro- Gly-Thr-Gly-Pro-Gly-Val-Gly- Asn-Gly-Gly-Phe-Gly-His-Gly-

Val-Gly-Asn-R' (IV) (SEQ ID NO: 4)

where R is H- or COCH<sub>3</sub>, R' is COOH or CONH<sub>2</sub> and each amino acid has the L or D configuration.

Claim 12. (New) A pharmaceutical composition comprising an effective dose of at least a peptide compound selected from the group consisting of:

R-Asn-Gly-Val-Gly- His- Gly-Phe-Gly-Asn-Gly-Val-Gly-Pro-Gly-Thr-Gly-Pro-Gly-Ser-  
Gly-R' (I) (SEQ ID NO: 1) and

R-Gly-Ser-Gly- Pro- Gly-Thr-Gly-Pro-Gly-Val-Gly- Asn-Gly-Gly-Phe-Gly-His-Gly-  
Val-Gly-Asn-R' (IV) (SEQ ID NO: 4)

where R is H- or COCH<sub>3</sub>, R' is COOH or CONH<sub>2</sub> and each amino acid has the L or D configuration, and at least one pharmaceutically acceptable inert ingredient.

Claim 13. (New) A method of treating a patient suffering from Multiple Sclerosis, comprising:

administering to a patient in need thereof an effective amount of a peptide compound selected from the group consisting of:

R-Asn-Gly-Val-Gly- His- Gly-Phe-Gly-Asn-Gly-Val-Gly-Pro-Gly-Thr-Gly-Pro-Gly-Ser-  
Gly-R' (I) (SEQ ID NO: 1) and

R-Gly-Ser-Gly- Pro- Gly-Thr-Gly-Pro-Gly-Val-Gly- Asn-Gly-Gly-Phe-Gly-His-Gly-  
Val-Gly-Asn-R' (IV) (SEQ ID NO: 4)

where R is H- or COCH<sub>3</sub>, R' is COOH or CONH<sub>2</sub> and each amino acid has the L or D configuration.